Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : bolsters its position on multiple sclerosis with a $765M BTK licensing deal

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 05:12pm CEST

Sanofi is snapping up an early-stage program from San Franciscos Principia Biopharma, shoring up the pharma giants position in multiple sclerosis.

Sanofi will write a check for $40 million upfront, with future milestone payments that could total $765 million. In return, Sanofi gets a worldwide license to develop and sell PRN2246. The asset, which just entered Phase I clinical trials, is a BTK inhibitor designed to access the brain and spinal column by crossing the blood-brain barrier. Once there, its meant to impact immune cell and brain cell signaling. The companies hope this may treat MS and other central nervous system diseases.

The asset makes sense for Sanofi, as the drug maker already has two successful MS drugs on the shelves: Aubagio and Lemtrada. The two products make up a significant part of Sanofis overall revenue.

Sanofis neuroscience research head Rita Balice-Gordon said the investment highlights Sanofis focus on MS and neurological disease.

Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases, Balice-Gordon said.

Principias CEO Martin Babler said partnering with a pharma giant with MS experience allows the startup to make better use of its resources.

The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area, Babler said.

The companys lead program, PRN1008, is in Phase II trials in patients with pemphigus, an orphan autoimmune disease.

The deal between Sanofi and Principia is a tad open-ended. Principia has the option to co-fund Phase III development, should the asset progress that far. If they choose that option, they can get increased royalties on global sales or a profit and loss sharing agreement in the US.

The transaction is expected to close in the fourth quarter.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
07/17SANOFI : 11th Dengvaxia complaint filed vs. Garin, 36 others
07/17SANOFI : NBI files raps in Ombudsman vs. Aquino, others over Dengvaxia mess
07/17NBI TO OMBUDSMAN : Prosecute Noynoy, Abad, Garin, et al. for graft over dengue v..
07/16SANOFI : Disclosure of trading in own shares
07/12SANOFI : to further accelerate its scientific presence with the opening of a Glo..
07/12SANOFI : Nesbitt School of Pharmacy at Wilkes University Partners With Sanofi Pa..
07/11SANOFI : shut down French plant over "astronomical" emission levels
07/10SANOFI : denounces CADTH negative recommendation that could limit treatment opti..
07/10SANOFI : France launches 100 million euros biotech fund
07/10SANOFI : Mourenx Plant to Remain Shut Until Emissions, Safety Requirements Met
More news
News from SeekingAlpha
07/16Aquestive Therapeutics Readies $60 Million IPO 
07/12Constellation Pharmaceuticals Readies $80 Million IPO Plans 
07/10A Wormhole View Of Voyager's Parkinson's Gene Therapy 
07/10BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Catabasis Nears Phase 3 Start, Regulus Sl.. 
07/09Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growin.. 
Financials (€)
Sales 2018 35 048 M
EBIT 2018 8 298 M
Net income 2018 5 080 M
Debt 2018 15 904 M
Yield 2018 4,20%
P/E ratio 2018 17,22
P/E ratio 2019 16,08
EV / Sales 2018 3,02x
EV / Sales 2019 2,85x
Capitalization 89 820 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 78,2 €
Spread / Average Target 9,1%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-0.01%105 236
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-4.54%201 464
ROCHE HOLDING LTD.-5.78%201 132
MERCK AND COMPANY11.23%169 193